Cor Vasa 2022, 64(4):468-473 | DOI: 10.33678/cor.2021.119

(Fukutinopathy as a rare cause of dilated cardiomyopathy and subclinical skeletal myopathy - a case report and review of cardiac involvement in skeletal muscle disease)

Kateřina Bouzkováa, Miloš Kubáneka, Alice Krebsováa, Lenka Piherováb, Petr Ridzoňc, Tomáš Roubíčekd, Stanislav Kmochb, Vojtěch Melenovskýa, Josef Kautzner
a Klinika kardiologie, Institut klinické a experimentální medicíny, Praha
b Laboratoř lékařské genomiky a bioinformatiky, Klinika dětského a dorostového lékařství, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze, Praha
c Klinika neurologie, 3. lékařská fakulta Univerzity Karlovy a Fakultní Thomayerova nemocnice, Praha
d Kardiocentrum, Krajská nemocnice Liberec, a.s., Liberec

Fukutinopathy belongs to α-dystroglykanopathies, autosomal recessive inherited skeletal muscle myopathies with a variable cardiac involvement. The disease was discovered in Japan with endemic occurrence as Fukuyama congenital skeletal dystrophy. However, it can be rarely diagnosed also in other countries with a different genetic architecture. We present a case of fukutinopathy in a young male of Czech origin with dilated cardiomyopathy and elevation of creatine phosphokinase. Neurologic assessment revealed just borderline signs of skeletal muscle myopathy. Whole-exome sequencing revealed in one allele a pathogenic missense variant of fukutin (FKTN) His172Leu, which was accompanied by a large deletion of exons 1-9 in the second allele of FKTN acting as a homozygous variant. Cardiac and neurologic status of the patient remained stable in the last four years. Recently, the patient has been diagnosed with a large epidermoid cyst of the fourth brain chamber causing a brainstem compression, which required a neurosurgical intervention. The finding could be related to congenital cerebral abnormalities seen in patients with fukutinopathies. In the context of this rare disease, we discuss diagnostics and management of cardiomyopathies associated with a skeletal muscle myopathy.

Keywords: Cardiomyopathy, Fukutin, Neuromuscular disease, Skeletal muscle dystrophy

Received: July 24, 2021; Revised: September 28, 2021; Accepted: October 16, 2021; Published: September 1, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bouzková K, Kubánek M, Krebsová A, Piherová L, Ridzoň P, Roubíček T, et al.. (Fukutinopathy as a rare cause of dilated cardiomyopathy and subclinical skeletal myopathy - a case report and review of cardiac involvement in skeletal muscle disease). Cor Vasa. 2022;64(4):468-473. doi: 10.33678/cor.2021.119.
Download citation

References

  1. Feingold B., Mahle W., Auerbach S., et al. Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association. Circulation 2017;136:e200-e231. Go to original source... Go to PubMed...
  2. Gilroy J, Cahalan JL, Berman R, Newman M. Cardiac and pulmonary complications in Duchenne's progressive muscular dystrophy. Circulation 1963;27(4 Pt 1):484-493. Go to original source... Go to PubMed...
  3. Barresi R, Campbell KP. Dystroglycan: from biosynthesis to pathogenesis of human disease. J Cell Sci 2006;119(Pt 2):199-207. Go to original source... Go to PubMed...
  4. Murakami T, Nishino I. [Fukuyama congenital muscular dystrophy and related alpha-dystroglycanopathies]. Brain Nerve 2008;60:1159-1164. Go to PubMed...
  5. Ujihara Y, Kanagawa M, Mohri S, et al. Elimination of fukutin reveals cellular and molecular pathomechanisms in muscular dystrophy-associated heart failure. Nat Commun 2019;10:5754. Go to original source... Go to PubMed...
  6. Fukuyama Y, Kawazura M, Haruna H. A peculiar form of congenital progressive muscular dystrophy: report of fifteen cases. Paediat. Univ Tokyo 1960;4:5-8.
  7. Hirasawa-Inoue A, Sato N, Shigemoto Y, et al. New MRI Findings in Fukuyama Congenital Muscular Dystrophy: Brain Stem and Venous System Anomalies. AJNR Am J Neuroradiol 2020;41:1094-1098. Go to original source... Go to PubMed...
  8. Vuillaumier-Barrot S, Quijano-Roy S, Bouchet-Seraphin C, et al. Four Caucasian patients with mutations in the fukutin gene and variable clinical phenotype. Neuromuscul Disord 2009;19:182-188. Go to original source... Go to PubMed...
  9. Yis U, Uyanik G, Heck PB, et al. Fukutin mutations in non- -Japanese patients with congenital muscular dystrophy: less severe mutations predominate in patients with a non-Walker- -Warburg phenotype. Neuromuscul Disord 2011;21:20-30. Go to original source... Go to PubMed...
  10. Arimura T, Hayashi YK, Murakami T, et al. Mutational analysis of fukutin gene in dilated cardiomyopathy and hypertrophic cardiomyopathy. Circ J 2009;73:158-161. Go to original source... Go to PubMed...
  11. Rapezzi C, Arbustini E, Caforio ALP, et al. Diagnostic work--up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statment from the ESC Working Group on Myocardial and Percardial Diseases. Eur Heart J 2013;5:1448-1458. Go to original source... Go to PubMed...
  12. van Spaendonck-Zwarts KY, van Rijsingen IA, van den Berg MP, et al. Genetic analysis in 418 index patients with idiopathic dilated cardiomyopathy: overview of 10 years' experience. Eur J Heart Fail 2013;15:628-636. Go to original source... Go to PubMed...
  13. Griggs RC, Moxley RT 3rd, Mendell JR, et al. Clinical Investigation of Duchenne Dystrophy Group. Prednisone in Duchenne dystrophy: a randomized, controlled trial defining the time course and dose response. Arch Neurol 1991;48:383-388. Go to original source... Go to PubMed...
  14. Duboc D, Meune C, Lerebours G, et al. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 2005;45:855-857. Go to original source... Go to PubMed...
  15. Duboc D, Meune C, Pierre B, et al. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up. Am Heart J 2007;154:596-602. Go to original source... Go to PubMed...
  16. Lowe J, Roble SL, Cripe LH. Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2015;14:153-161. Go to original source... Go to PubMed...
  17. Bourke JP, Bueser T, Quinlivan R. Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy. Cochrane Database Syst Rev 2018;10(10):CD009068. Go to original source... Go to PubMed...
  18. Bourke JP, Watson G, Muntoni F, et al; DMD Heart Protection study group. Randomised placebo-controlled trial of combination ACE inhibitor and beta-blocker therapy to prevent cardiomyopathy in children with Duchenne muscular dystrophy? (DMD Heart Protection Study): a protocol study. BMJ Open 2018;8:e022572. Go to original source... Go to PubMed...
  19. Hromaníková K, Kubánek M, Krebsová A, et al. Záchyt laminopatie s převažujícím postižením srdce v rámci předtransplantační diagnostiky - kazuistika, rozbor rizikové stratifikace a kardiologického managementu pacientů s laminopatií. Cor Vasa 2022,64:67-71. Go to original source...
  20. van Rijsingen IAW, Arbustini E, Elliott PM, et al. Risk Factors of Malignant Ventricular Arrhythmias in Lamin A/C Mutation Carriers. A European Cohort Study. J Am Coll Cardiol 2012;59:493-500. Go to original source... Go to PubMed...
  21. Wahbi K, Yaou RB, Gandjbakhch E, et al. Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies. Circulation 2019;140:293-302. Go to original source... Go to PubMed...
  22. Priori AG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patiens with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2015;36:2793-2867. Go to original source... Go to PubMed...
  23. Wahbi K, Furling D. Cardiovascular manifestations of myotonic dystrophy. Trends Cardiovasc Med 2020;30:232-238. Go to original source... Go to PubMed...
  24. Groh WJ, Groh MR, Saha C, et al. Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med 2008;358:2688-2697. Go to original source... Go to PubMed...
  25. Wahbi K, Meune C, Porcher R, et al. Electrophysiological study with prophylactic pacing and survival in adults with myotonic dystrophy and conduction system disease. JAMA 2012;307:1292-1301. Go to original source... Go to PubMed...
  26. Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2019;74:e51-e156.
  27. Čihák R, Haman L, Táborský M. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Summary of the document prepared by the Czech Society of Cardiology. Cor Vasa 2016;58:e636-e683. Go to original source...

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.





Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.